Up­dat­ed: Bridge­Bio inks $100M up­front deal with Ky­owa Kirin for skele­tal dis­or­der drug

Bridge­Bio will pock­et $100 mil­lion as it part­ners with Japan­ese phar­ma Ky­owa Kirin to ex­plore the use of in­fi­gra­tinib in sev­er­al skele­tal dis­or­ders, the com­pa­nies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER